Palisade Bio
PALI
Market cap $5.25M

1.77 USD

+0.06

3.51%

Updated Dec 26, 11:11 AM EST

1 day

3.51%

5 days

-1.12%

1 month

-26.86%

3 months

-47.48%

6 months

-61.35%

Year to date

-79.61%

1 year

-80.22%

5 years

-99.98%

10 years

-99.98%

About: Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Employees: 9

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,809 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

62% more capital invested

Capital invested by funds: $136K [Q2] → $220K (+$84.5K) [Q3]

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

14% more funds holding

Funds holding: 7 [Q2] → 8 (+1) [Q3]

2.05% more ownership

Funds ownership: 3.21% [Q2] → 5.26% (+2.05%) [Q3]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$8

352%

upside

Avg. target

$23

1,199%

upside

High target

$38

2,047%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Brookline Capital Kumaraguru Raja 50% 1-year accuracy 2 / 4 met price target	2,047%upside $38	Buy Initiated	20 Nov 2024
Maxim Group Naz Rahman 8% 1-year accuracy 1 / 12 met price target	352%upside $8	Buy Maintained	13 Nov 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about PALI published over the past 30 days

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Carlsbad, CA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases, today announced the appointment of Brian G. Feagan, MD, FRCPC, to its Clinical Advisory Board.

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Carlsbad, CA, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $5 million prior to deducting underwriting commissions and offering expenses. The offering is comprised of (i) 158,000 Class A Units with each unit consisting of (a) one share of common stock and (b) one common warrant to purchase one share of common stock (the “Common Warrants”), and (ii) 3,120,688 Class B Units with each unit consisting of (a) one prefunded common stock purchase warrant to purchase one share of common stock (“Prefunded Warrants”) and (b) one Common Warrant. The price per Class A Unit is $1.525 and the price per Class B Unit is $1.5249 (collectively, the “Offering”).

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

What's Going On With Palisade Bio Stock On Thursday?

On Thursday, Palisade Bio Inc PALI stock is trading higher with a strong session volume of 26.97 million, compared to an average volume of 107.68k as per data from Benzinga Pro.

What's Going On With Palisade Bio Stock On Thursday?

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Carlsbad, CA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced the pricing of an underwritten public offering for gross proceeds of approximately $5 million prior to deducting underwriting commissions and offering expenses. The offering is comprised of (i) 158,000 Class A Units with each unit consisting of (a) one share of common stock and (b) one common warrant to purchase one share of common stock (the “Common Warrants”), and (ii) 3,120,688 Class B Units with each unit consisting of (a) one prefunded common stock purchase warrant to purchase one share of common stock (“Prefunded Warrants”) and (b) one Common Warrant. The price per Class A Unit is $1.525 and the price per Class B Unit is $1.5249 (collectively, the “Offering”).

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

First three Single Ascending Dose cohorts demonstrated no treatment related adverse events Carlsbad, CA, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc, (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced preliminary results from its first three single ascending dose (SAD) cohorts in its ongoing Phase 1 human clinical study for PALI-2108 for the treatment of Ulcerative Colitis (UC). The ongoing Phase 1 study is evaluating PALI-2108 in a single-center, double-blind, placebo-controlled study focused on safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in healthy volunteers, alongside an open-label study involving a patient cohort with UC.

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Data to be presented at the 8 th Annual Antifibrotic Drug Development (AFDD) Summit PALI-2108 may offer a solution for fibrostenotic Crohn's disease by enhancing efficacy, safety, and therapeutic potential compared to traditional treatments Carlsbad, CA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases, today announced preclinical results for PALI-2108, a novel local PDE4 inhibitor prodrug. In recent studies using the Dextran Sulfate Sodium (DSS) colitis mouse model, PALI-2108 demonstrated a dose-dependent effect on key fibrotic pathways, underscoring its potential as an effective treatment for fibrostenotic Crohn's disease.

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Commenced enrollment and dosing in Phase 1 clinical study of PALI-2108 for the treatment of moderate-to-severe Ulcerative Colitis (UC)

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and reduced side effects, potentially enhancing patient compliance compared to existing PDE4 inhibitors Data presented at the American College of Gastroenterology's (ACG) 2024 Annual Scientific Meeting Carlsbad, CA, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company dedicated to developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases has announced the presentation of data from two translational studies demonstrating the ex vivo bioactivation of PALI-2108 in stool samples and whole blood. This orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development for patients with ulcerative colitis (UC).

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

– Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA)

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

See News Rankings

Charts implemented using Lightweight Charts™